> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Orphan Designation Granted for Escend Leukemia Drug
- URL: https://www.fdaweb.com/orphan-designation-granted-for-escend-leukemia-drug/
- Published: 2016-06-03T12:00:00.000Z
- Updated: 2026-09-14T21:07:22.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135835

FDA has granted Escend Pharmaceuticals an orphan drug designation for ES-3000 and its use for treating chronic myeloid leukemia (CML). ES-3000 is an orally bioavailable small molecule which ablates leukemic stem cells by reducing β-catenin expression through a novel mechanism of action, according to the company. The drug is also in development for treating acute myeloid leukemia and triple negative breast cancer. “Due to the resistance of leukemic stem cells to tyrosine kinase inhibitors, minimal residual disease in CML patients is an unmet need which will be addressed with ES-3000.,” it says.